Desh Rakshak AushdhalayaBOM:531521 61 EBITDA Margin % is 18.30% as of Mar. 2026, which is 6% above its 10-year median of 17.29. GuruFocus rates BOM:531521 with a GF Score™ of 61/100 and a GF Value™ of ₹18.38 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Desh Rakshak Aushdhalaya ranks better than 67.26% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Desh Rakshak Aushdhalaya EBITDA Margin % Related Terms
Desh Rakshak Aushdhalaya EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531521 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Desh Rakshak Aushdhalaya's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Desh Rakshak Aushdhalaya EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Desh Rakshak Aushdhalaya's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Desh Rakshak Aushdhalaya's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Desh Rakshak Aushdhalaya (BOM:531521) has a EBITDA Margin % of 18.30% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Desh Rakshak Aushdhalaya and its competitors. This is near median its historical median of 17.29. Over the past decade, Desh Rakshak Aushdhalaya's EBITDA Margin % has ranged from 11.16 to 21.69. According to the industry distribution chart, Desh Rakshak Aushdhalaya ranks #313 out of 956 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is Desh Rakshak Aushdhalaya's EBITDA Margin % too high?
Desh Rakshak Aushdhalaya's current EBITDA Margin % of 18.30% is near median its 10-year median of 17.29. Over the past 10 years, this metric has ranged from a low of 11.16 to a high of 21.69. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Desh Rakshak Aushdhalaya's value of 18.30% is 46.2% above this industry median. Based on the distribution chart, Desh Rakshak Aushdhalaya ranks #313 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Desh Rakshak Aushdhalaya has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Desh Rakshak Aushdhalaya's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Desh Rakshak Aushdhalaya ranks #313 out of 956 companies for EBITDA Margin %. This puts Desh Rakshak Aushdhalaya in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Desh Rakshak Aushdhalaya's value of 18.30% is 46.2% above this benchmark. Historically, Desh Rakshak Aushdhalaya's own EBITDA Margin % has ranged from 11.16 to 21.69 over the past decade. While the company's 10-year median is 17.29 vs. the industry median of 12.52, Desh Rakshak Aushdhalaya has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Desh Rakshak Aushdhalaya's current EBITDA Margin % of 18.30% is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Desh Rakshak Aushdhalaya and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Desh Rakshak Aushdhalaya's current EBITDA Margin % is 18.30%, which is near median its own 10-year median of 17.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Desh Rakshak Aushdhalaya stock overvalued right now?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya (BOM:531521) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.38, compared to a current price of ₹32.59 — trading 77.3% above its estimated fair value. The current EBITDA Margin % is 18.30%, which is near median its 10-year median of 17.29 and 46.2% above the Drug Manufacturers industry median of 12.52. Desh Rakshak Aushdhalaya's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Desh Rakshak Aushdhalaya (BOM:531521), the current EBITDA Margin % is 18.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Desh Rakshak Aushdhalaya (BOM:531521) Overvalued in 2026?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya stock appears to be overvalued.
The current stock price of ₹32.59 is trading 77.3% above its estimated GF Value™ of ₹18.38.
GuruFocus considers Desh Rakshak Aushdhalaya to be Significantly Overvalued.
Key valuation signals for BOM:531521:
EBITDA Margin %: 18.30% (near median its 10-year median of 17.29)
GF Value™: ₹18.38 vs. price of ₹32.59 (77.3% above fair value)
Industry Position: 46.2% above the Drug Manufacturers median (#313 of 956)
No single metric tells the full story. See the BOM:531521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Desh Rakshak Aushdhalaya Ltd manufactures and sells ayurvedic and herbal products in India. The firm offers ayurvedic patents & proprietary medicines with herbs. It provides classical and patent medicines in tablet and capsule, powder, and liquid forms. Products ranging from AmalkiChurna, Ashwagandha Tablet, TriphalaChurna, LavanaBhaskarChurna, Sat-Shilajeet, ShunthiChurna, HingwadiChurna, GasharVati, BuddhivardhakYog, Balamrit, LodhraChurna, and Others.
61GF Score
Get the complete analysis for BOM:531521
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531521 has been successfully added to your 
